While some information on these therapeutic candidates is restricted by confidentiality agreements, in the table below you will find links that offer more information about disclosed assets. We provide this information for informational purposes only.
| Marketer | Asset Name | Target | Royalty Rate | Clinical Trials | Product Website | |
|---|---|---|---|---|---|---|
| Daré Bioscience | DARE TO PLAY™ | PDE-5 inhibitor | Low single digit | product website | ||
| Day One | OJEMDA™ (tovorafenib) | Pan-RAF inhibitor | Mid-single digit | clinical trials | ||
| Medexus | IXINITY® | Recombinant Factor IX | Mid-single digit | product website | ||
| Organon | XACIATO™ | Bacterial vaginal infection | High single digit | product website | ||
| Roche | VABYSMO® (faricimab-svoa) | Angiopoietin-2 and VEGF-A bispecific antibody | 0.5% | clinical trials | ||
| Talphera | DSUVIA® (sufentanil sublingual tablet) | Acute pain treatment | 37.5-75% (DoD) | clinical trials | product website | |
| Zevra | MIPLYFFA™ (arimoclomol) | Heat-shock protein amplifier | Mid-single digit | clinical trials | product website |
| Developer | Asset Name | Target | Royalty Rate | Clinical Trials | ||
|---|---|---|---|---|---|---|
| AstraZeneca | Rilvegostomig (AZD2936) | TIGIT/PD-1 bispecific antibody | Undisclosed | clinical trials | ||
| AVEO, an LG Chem company | Ficlatuzumab (AV-299) | HGF antibody | Low single digit | clinical trials | ||
| Castle Creek Biosciences | D-Fi (FCX-007) | Gene therapy | <1.0% | clinical trials | ||
| Chiesi & Gossamer | Seralutinib | Inhaled PDGFR, CSF1R, c-KIT inhibitor | Low to mid-single digit, net | clinical trials | ||
| Daré Bioscience | Ovaprene® | Hormone-free contraceptive | Low single digit | clinical trials | ||
| Johnson & Johnson | Cetrelimab (JNJ-63723283) | PD-1 antibody | 0.75% | clinical trials | ||
| Mirum Pharmaceuticals | Volixibat | Ileal bile acid transporter (IBAT) inhibitor | Low to mid-single digit | clinical trials | ||
| Oak Hill Bio | OHB-607 | Recombinant human IGF-I/IGFBP-3 | Low to mid-single digit | clinical trials | ||
| Recursion Pharmaceuticals | REC-4881 | Allosteric MEK1/2 inhibitor | Low to mid-single digit | clinical trials | ||
| Rezolute | Ersodetug (RZ358) | INSR antibody | High single digit to mid teens | clinical trials | ||
| Takeda | Mezagitamab (TAK-079) | CD-38 antibody | Low single digit | clinical trials | ||
| Takeda in Japan & Partner outside of Japan | Osavampator | Alpha-amino-3-hydroxy-5-methyl-4 isoxazole propionic acid (AMPA) positive allosteric modulator | Low to mid-single digit | clinical trials |
| Developer | Asset Name | Target | Royalty Rate | Clinical Trials | ||
|---|---|---|---|---|---|---|
| Aronora | AB023 | Factor XI/Xia | Low single digit | clinical trials | ||
| Celyn Therapeutics | KIN-8741 | c-MET | Not disclosed | |||
| Compugen | COM902 | TIGIT antibody | Undisclosed | clinical trials | ||
| Daré Bioscience | Sildenafil cream, 3.6% | PDE-5 inhibitor | Low single digit | clinical trials | ||
| Johnson & Johnson | JNJ-89853413 | Bispecific Vδ2 T-cell engager | Low single digit | clinical trials | ||
| Khora | KIN-3248 | FGFR | None | clinical trials | ||
| Khora | Undisclosed | CDK2/4 | None | |||
| Khora | Undisclosed | CDK4 | None | |||
| Lifordi | LFD-200 | VISTA ADC | 0.75% | clinical trials | ||
| Merck | MK-4830 | ILT-4 | Not disclosed | clinical trials | ||
| Moderna | Undisclosed | T-Cell | Mid-single digit | |||
| Molecular Templates | MT-0169 | Anti-CD-38 immunotoxin | 4% | clinical trials | ||
| Monopar Therapeutics | MNPR-101 | Urokinase plasminogen activator receptor (uPAR) radioimmunotherapeutic | None | |||
| Mosaica Therapeutics | KIN-7136 | MEK | Not disclosed | |||
| National Resilience | G03-52-01 | Botulinum neurotoxin antibodies | 15% | |||
| Oak Hill Bio | Five early-stage assets | Multiple targets | Low to mid-single digit | |||
| Palobiofarma | PBF-680 | Adenosine A1 receptor inhibitor | Low single digit | clinical trials | ||
| Palobiofarma | PBF-677 | Adenosine A3 receptor inhibitor | Low single digit | clinical trials | ||
| Palobiofarma | PBF-999 | Adenosine A2a receptor/ PDE-10 inhibitor | Low single digit | clinical trials | ||
| Palobiofarma | PBF-1129 | Adenosine A2b receptor inhibitor | Low single digit | clinical trials | ||
| Palobiofarma | PBF-1650 | Adenosine A3 receptor inhibitor | Low single digit | clinical trials | ||
| Pfizer | PF-08046052 | Anti-EGFR bispecific γδ T-cell engager | Low single digit | clinical trials | ||
| Regeneron | Vidutolimod (CMP-001) | Virus-like particle containing a TLR9 agonist | High single digit to double digit | clinical trials | ||
| Rezolute | AB101 | Injectable basal insulin | Low single digit | |||
| Rezolute | RZ-402 | Plasma kallikrein inhibitor | Low single digit | clinical trials | ||
| Twist Bioscience's 30+ partners | 60+ early-stage assets | Multiple targets | 50% of up to low single digits |
All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
